SCHEMBL18318693

SCHEMBL18318693

CC(C)C(=O)N1CCC(Oc2ccc(-c3ccc4cccnc4c3)nc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
BMPR1B O00238 1/20 0.41
BMPR1A P36894 1/20 0.41
ACVRL1 P37023 1/20 0.41
ACVR1 Q04771 1/20 0.41
GSK3B P49841 1/20 0.41
NAMPT P43490 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HRH3 Q9Y5N1 3/20 0.39
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
FASN P49327 1/20 0.39
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
PDE10A Q9Y233 1/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
MTOR P42345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18318847 0.89 GSK3B (0.47) GSK3BNAMPTALDH1A1HRH3FASN
SCHEMBL18318829 0.88 GSK3B (0.47) CYP4F2CYP4A11BMPR1BBMPR1AACVRL1
SCHEMBL18318882 0.87 CYP4F2 (0.46) CYP4F2CYP4A11BMPR1BBMPR1AACVRL1
SCHEMBL18318266 0.85 CYP4F2 (0.47) CYP4F2CYP4A11GSK3BNAMPTALDH1A1
SCHEMBL18318596 0.83 PIK3CA (0.55) CYP4F2CYP4A11NAMPTHRH3GPR119
SCHEMBL18318901 0.83 NAMPT (0.52) GSK3BNAMPTHRH3FASNPIK3CD
Hydrochloric Acid SCHEMBL28550552 0.82 NAMPT (0.51) GSK3BNAMPTHRH3FASNPIK3CD
SCHEMBL18318175 0.81 ALDH1A1 (0.44) NAMPTALDH1A1HRH3PIK3CDPIK3CA
SCHEMBL18318811 0.80 KMO (0.44) GSK3BNAMPTFASNNTRK1KCNH2
SCHEMBL18318797 0.77 SRD5A1 (0.48) CYP4F2CYP4A11NAMPTALDH1A1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702388-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2023-07-18 US claimed
US-20210230116-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2021-07-29 US claimed
CN-107847765-B 1, 4-substituted piperidine derivatives 89生物有限公司 2021-05-04 CN claimed
EP-3310441-B1 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES 89BIO LTD (IL) 2020-07-29 EP claimed
US-9902696-B2 1,4-substituted piperidine derivatives CEPHALON, INC. (US) 2018-02-27 US claimed
US-20250257035-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2025-08-14 US disclosed
US-12098130-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2024-09-24 US disclosed
US-20230391723-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2023-12-07 US disclosed
US-11702388-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2023-07-18 US disclosed
US-11702388-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2023-07-18 US disclosed
US-11702388-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2023-07-18 US disclosed
US-20210230116-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2021-07-29 US disclosed
US-20180179159-A1 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES CEPHALON LLC 2018-06-28 US disclosed
US-20180179159-A1 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES CEPHALON LLC 2018-06-28 US disclosed
US-9902696-B2 1,4-substituted piperidine derivatives CEPHALON, INC. (US) 2018-02-27 US disclosed
US-9902696-B2 1,4-substituted piperidine derivatives CEPHALON, INC. (US) 2018-02-27 US disclosed
US-9902696-B2 1,4-substituted piperidine derivatives CEPHALON, INC. (US) 2018-02-27 US disclosed
US-20160368874-A1 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES CEPHALON LLC 2016-12-22 US disclosed
US-20160368874-A1 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES CEPHALON LLC 2016-12-22 US disclosed
WO-2016205633-A1 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES CEPHALON, INC. (US) 2016-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257035-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A CYP4F2 277/4885CYP4A11 297/4885BMPR1B 3436/4885
US-20230391723-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A CYP4F2 277/4885CYP4A11 297/4885BMPR1B 3436/4885
US-20160368874-A1 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES FASN, CES1, CPT1A CYP4F2 277/4885CYP4A11 297/4885BMPR1B 3436/4885
US-20210230116-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A CYP4F2 277/4885CYP4A11 297/4885BMPR1B 3436/4885
US-11702388-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A CYP4F2 277/4885CYP4A11 297/4885BMPR1B 3436/4885
US-12098130-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A CYP4F2 277/4885CYP4A11 297/4885BMPR1B 3436/4885
US-20180179159-A1 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES FASN, CES1, CPT1A CYP4F2 273/4885CYP4A11 299/4885BMPR1B 3529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.